相似文献
1
Provisional WHO/UNAIDS recommendations on the use of contrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa.
Afr Health Sci. 2001 Aug;1(1):30-1.
2
Africa: children's access to prophylaxis may improve after medical study, new WHO recommendations.
AIDS Treat News. 2004 Nov-Dec(407-408):8-9.
3
Reconsidering empirical cotrimoxazole prophylaxis for infants exposed to HIV infection.
Bull World Health Organ. 2004 Apr;82(4):290-7.
4
Cotrimoxazole prophylaxis for infants exposed to HIV infection.
Bull World Health Organ. 2004 Apr;82(4):297-8.
5
Cotrimoxazole prophylaxis for HIV-positive TB patients in developing countries.
Trop Doct. 2006 Apr;36(2):79-82. doi: 10.1258/004947506776593314.
6
7
Editorial response: Prophylaxis for Pneumocystis carinii pneumonia--an evolving tale of two populations.
Clin Infect Dis. 1999 Oct;29(4):784-6. doi: 10.1086/520434.
8
Protect yourself from Pneumocystis carinii.
AIDS Alert. 1999 Jun;14(6):suppl 1-2.
9
Discontinuing prophylaxis against Pneumocystis carinii pneumonia.
N Engl J Med. 2001 May 24;344(21):1639; author reply 1640-1.
10
Pneumocystis jiroveci pneumonia in AIDS patients: reactivation, reinfection or both?
Int J STD AIDS. 2003 Sep;14(9):644-5. doi: 10.1258/095646203322301176.
引用本文的文献
1
Neonates exposed to HIV but uninfected exhibit an altered gut microbiota and inflammation associated with impaired breast milk antibody function.
Microbiome. 2024 Dec 20;12(1):261. doi: 10.1186/s40168-024-01973-z.
2
Reasons for implementation success despite health system constraints: qualitative insights on 'what worked' for cotrimoxazole preventive therapy.
BMC Health Serv Res. 2024 Mar 27;24(1):379. doi: 10.1186/s12913-024-10631-x.
3
Co-trimoxazole prophylaxis for children who are HIV-exposed and uninfected: a systematic review.
J Int AIDS Soc. 2023 Jun;26(6):e26079. doi: 10.1002/jia2.26079.
4
Clinicopathological correlation of kidney disease in HIV infection pre- and post-ART rollout.
PLoS One. 2022 May 31;17(5):e0269260. doi: 10.1371/journal.pone.0269260. eCollection 2022.
5
Mixed methods systematic review and metasummary about barriers and facilitators for the implementation of cotrimoxazole and isoniazid-Preventive therapies for people living with HIV.
PLoS One. 2022 Mar 1;17(3):e0251612. doi: 10.1371/journal.pone.0251612. eCollection 2022.
6
Types and prevalence of HIV-related opportunistic infections/conditions among HIV-positive patients attending Kenyatta National Hospital in Nairobi, Kenya.
Afr Health Sci. 2020 Jun;20(2):615-624. doi: 10.4314/ahs.v20i2.9.
7
Use of non-HIV medication among people living with HIV and receiving antiretroviral treatment in Côte d'Ivoire, West Africa: A cross-sectional study.
PLoS One. 2019 Sep 16;14(9):e0221335. doi: 10.1371/journal.pone.0221335. eCollection 2019.
8
AIDS and tuberculosis in medical inpatients in Malawi.
Malawi Med J. 2002 Sep;14(2):19-20. doi: 10.4314/mmj.v14i2.10762.
9
Evaluation of cotrimoxazole use as a preventive therapy among patients living with HIV/AIDS in Gondar University Referral Hospital, northwestern Ethiopia: a retrospective cross-sectional study.
HIV AIDS (Auckl). 2016 Jul 7;8:125-33. doi: 10.2147/HIV.S103081. eCollection 2016.
10
CD14(+) macrophages that accumulate in the colon of African AIDS patients express pro-inflammatory cytokines and are responsive to lipopolysaccharide.
BMC Infect Dis. 2015 Oct 17;15:430. doi: 10.1186/s12879-015-1176-5.
Zotero 插件